Infectious Diseases

Whole-genome sequencing revealed extensive NICU transmission of MSSA and MRSA strains linked to invasive infection.

The AAP released its 2026 childhood immunization schedule, maintaining evidence-based vaccine recommendations and expanding guidance across routine, catch-up, and risk-based care.

FDA-cleared Flowflex Plus 4-in-1 home test detects RSV, influenza A/B, and COVID-19 in adults and children as young as 6 months.

Influenza antiviral use among hospitalized US children declined during the late COVID-19 pandemic despite guideline recommendations.

Long-acting injectable HIV treatment given every 2 months was safe, well tolerated, and strongly preferred by adolescents in a recent study.

Adolescents with HIV reported strong preference, viral suppression, and favorable safety outcomes after switching to long-acting injectable treatment.

Pertussis often presents as a prolonged cold, especially in infants. Early recognition, treatment, and vaccination are key to reducing severe disease and spread.

Starting HPV vaccination earlier improves access, builds trust with families, and increases uptake before virus exposure to prevent cancer.

Experts say recent CDC vaccine schedule changes may complicate clinician–family communication without altering the underlying evidence supporting pediatric vaccination.

Maternal influenza and TDaP vaccination during pregnancy was associated with fewer influenza- and pertussis-related hospital and ED visits in infants younger than 6 months.

ACIP recommends use of GSK’s pentavalent MenACWY-CRM/MenB-4C vaccine when MenACWY and MenB are indicated at the same visit.

Reactions from the pediatric health care community poured in following swift changes to the US childhood vaccine schedule by the CDC.

Effective immediately, the updated US childhood vaccine schedule will reduce the number of recommended vaccines for all children to 11 diseases, down from 18.

Those with regular access to care who did not receive, or were late on 2- and 4-month recommended vaccines, were more likely to not have any MMR vaccine by 2 years of age.

In this recap article, take a look back at some of our top stories in the infectious diseases space in 2025.

“We started out 2025 with an environment that was rife with myths and disinformation," said Robert H. Hopkins, Jr., MD, in this year-end recap of 2025 and the pediatric vaccine landscape.

Climate lag time poses urgent health risks for children, necessitating proactive pediatric care and policy changes to address future climate-related challenges.

See the full case of our most recent Puzzler quiz and view the correct diagnosis of this 19-year-old woman with painful, purpuric nodules in the phalanges of her fingers.

Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, shares her thoughts on the recently updated ACIP recommendation on the hepatitis B vaccine.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

The FDA has approved Nuzolvence as a new single-dose oral option for uncomplicated urogenital gonorrhea in adults and children 12 years and older who weigh at least 77 pounds.

Phase 3 results show oral zoliflodacin was noninferior to ceftriaxone and azithromycin for uncomplicated urogenital gonorrhea.

This approval of gepotidacin is the first in a new antibiotic class for the treatment of gonorrhoea approved in over 3 decades.

According to multiple reports, the FDA is investigating the safety of a pair of already-approved protective treatments for respiratory syncytial virus.

“We took a different approach by looking at colonizing bacteria, and we found vaccination reduced antimicrobial resistance through a completely different mechanism," said Brooke Ramay, lead author of the study.